Accepted is not approved
Gene-therapy news runs on verbs that sit next to each other in a headline and mean different things at the agency: accept, review, approve. In nine days the two ends of that scale both showed up. One medicine crossed the line. The other is at the door, with a date by which someone has to say whether it comes in.
Families do not read the Federal Register on the bus. They read the headline. Secondary headlines in that fortnight treated acceptance of an application as if the drug were already licensed. The shorthand was “BLA approval.” In FDA usage that often means only that the file was complete enough to review. This page keeps the two stories apart by the documents, not by the adjective.
Fayuvi is a virus carrying a gene
On 17 September 2026 the FDA issued approval letter STN BL 125845/0. The product is Fayuvi. The proper name is rebisufligene etisparvovec-hopf. The company is Ultragenyx.
The indication is narrow, and it is worth copying rather than widening: neurologic manifestations of mucopolysaccharidosis type IIIA, Sanfilippo syndrome type A, in pediatric patients with preserved neurodevelopmental function. It is not a license for every person who has the disease.
The mechanism is gene replacement, and it is not CRISPR. An AAV9 virus delivers a working copy of the SGSH gene. One intravenous dose, so cells can make sulfamidase, the enzyme missing when that gene does not work. A working page is added. The text is not rewritten with molecular scissors.
Until this approval there was no FDA-approved therapy meant to change the course of MPS IIIA. Care was symptom management. The trials tied to this development are NCT02716246, NCT04360265, and NCT04088734. The program carried orphan, fast track, and breakthrough designations. Those labels move a file faster. The approval is the letter of 17 September.
lonvo-z has a filing, not a license
Nine days earlier, on 8 September, Intellia Therapeutics filed an 8-K with the SEC. The fact in it is specific: the FDA accepted the biologics license application for lonvoguran ziclumeran, lonvo-z, for hereditary angioedema, and granted priority review. The PDUFA target action date is 10 March 2027. The filing says the FDA is not currently planning an advisory committee.
Accepting a BLA means the package is complete enough to be read. It does not mean the medicine works, and it does not mean anyone can prescribe it. lonvo-z is not approved.
Casgevy, approved in 2023, is already a CRISPR medicine, prepared outside the body and given back as edited cells. That is not the same as editing inside the patient, and it is not this September’s news. “CRISPR approved” can name a drug from three years ago or jump ahead of one that does not exist yet. In this fortnight, the medicine that crossed the line does not use CRISPR.
| Fayuvi | lonvo-z | |
|---|---|---|
| What happened | Approval letter, 17 Sep 2026, STN BL 125845/0 | 8-K of 8 Sep 2026: FDA accepted the BLA and granted priority review |
| Approved? | Yes, for that pediatric indication | No. PDUFA target date 10 Mar 2027. No advisory committee currently planned |
| What it is | AAV9 gene replacement. One intravenous dose of a working SGSH gene. Not CRISPR | In vivo CRISPR. If approved: the first of that kind, and a one-time hereditary angioedema treatment |
| Who the paper covers | Neurologic manifestations of MPS IIIA in pediatric patients with preserved neurodevelopmental function | Hereditary angioedema: the indication on the application, not on an approval |
Said quietly, the fortnight is this. Fayuvi is a virus delivering a gene, and it has a letter. lonvo-z is CRISPR inside the body, and it has an accepted filing. Nine days, two statuses. Someone looking for a treatment for a child, or for themselves, needs that sentence before they need a shorter headline.